Clinical and Translational Research
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. Feb 15, 2024; 16(2): 331-342
Published online Feb 15, 2024. doi: 10.4251/wjgo.v16.i2.331
Table 1 Clinical and pathology characteristics
Item
All patients (n= 126)
Low BMI (n= 74)
High BMI (n= 52)
P value
General characteristics
Male85 (67.5)48 (64.9)37 (71.2)0.458
Age ≥ 60 yr54 (42.9)37 (50.0)17 (32.7)0.053
BMI, kg/m223.6 ± 3.521.2 ± 1.827.0 ± 2.3< 0.001
Weight gain ≥ 5%34 (27.0)18 (24.3)16 (30.8)0.254
Weight loss ≥ 5%17 (13.5)13 (17.6)4 (7.7)0.254
Hypertension50 (39.7)23 (31.1)27 (51.9)0.019
Diabetes20 (15.9)10 (13.5)10 (19.2)0.387
Primary colorectal tumour
Primary site, colon62 (49.2)37 (50.0)25 (48.1)0.832
Lymph nodal metastasis177 (68.8)49 (73.1)28 (62.2)0.222
Liver metastases
Synchronous83 (65.9)52 (70.3)31 (59.6)0.214
Bilobar distribution47 (37.3)26 (35.1)21 (40.4)0.549
Diameter of largest metastases ≥ 3.0 cm46 (36.5)24 (32.4)22 (42.3)0.257
Multiple metastases61 (48.4)36 (48.6)25 (48.1)0.950
Preoperative chemotherapy details
Oxaliplatin-based regimen95 (75.4)60 (81.1)35 (67.3)0.077
Bevacizumab45 (35.7)26 (35.1)19 (36.5)0.871
Cycles > 632 (25.4)18 (24.3)14 (26.9)0.741
Therapy delayed or dose reduced15 (11.9)9 (12.2)6 (11.5)0.915
Surgical details
Preoperative CEA ≥ 10 ng/mL52 (41.3)27 (36.5)25 (48.1)0.193
Laparoscopic101 (80.2)59 (79.7)42 (80.8)0.885
Simultaneous35 (27.8)16 (21.6)19 (36.5)0.066
Pringle manoeuver89 (70.6)51 (68.9)38 (73.1)0.614
Postoperative details
Morbidity (Dindo-Clavien II-V)29 (23.0)17 (23.0)12 (23.1)0.989
Length of hospital stay (median, Q1-Q3)8.0 (6.0-10.8)8.0 (6-10)8.0 (6-11.0)0.539
Pathology details
Complete tumour response27 (21.4)22 (29.7)5 (9.6)0.007
Steatosis56 (44.4)30 (40.5)26 (50.0)0.293
Sinusoidal dilatation103 (82.4)62 (84.9)41 (78.8)0.379
Severe steatosis (grade 2-3)17 (13.5)6 (8.1)11 (21.2)0.035
Severe sinusoidal dilatation (grade 2-3)30 (23.8)19 (25.7)11 (21.2)0.557